益气活血类中成药治疗脑梗死恢复期的网状Meta分析  

Network Meta-analysis of Yiqi Huoxue Chinese patent medicines in treatment of recovery period of cerebral infarction

作　　者：孟甜甜 解小龙 程江艳 郭亚萌 王鑫鑫 张靖泽 李明轩 高颖[2,3] 何庆勇[1] MENG Tian-tian;XIE Xiao-long;CHENG Jiang-yan;GUO Ya-meng;WANG Xin-xin;ZHANG Jing-ze;LI Ming-xuan;GAO Ying;HE Qing-yong(Guang’anmen Hospital,China Academy of Chinese Medical Sciences,Beijing 100700,China;Dongzhimen Hospital,Beijing University of Chinese Medicine,Beijing 100700,China;Institute for Brain Disorders,Beijing University of Chinese Medicine,Beijing 100700,China;The First Affiliated Hospital of Henan University of Traditional Chinese Medicine,Zhengzhou 450003,China)

机构地区：[1]中国中医科学院广安门医院,北京100700 [2]北京中医药大学东直门医院,北京100700 [3]北京中医药大学中医脑病研究院,北京100700 [4]河南中医药大学第一附属医院,河南郑州450003

出　　处：《中草药》2021年第21期6637-6647,共11页Chinese Traditional and Herbal Drugs

基　　金：“十三五”国家重点研发计划(2018YFC1705000,2018YFC1705001)。

摘　　要：目的基于网状Meta分析方法,比较不同益气活血类中成药在脑梗死恢复期治疗方面的差异。方法系统检索国内外中国知网、万方、维普、PubMed、Cochrane、EMbase等数据库,检索时限为自建库至2021年2月。查重筛选后,2名作者背对背提取文献资料,并采用Cochrane偏倚风险评估工具评价文献质量,采用Stata 16和GeMTC 14.3进行网状Meta分析。结果最终纳入45项研究,4355例患者,涉及6种益气活血类中成药。网状Meta分析显示,在改善总有效率方面,概率排序为脑心通胶囊+西医常规治疗(0.59)>复方地龙胶囊/片+西医常规治疗(0.18)>消栓肠溶胶囊+西医常规治疗(0.09)>灯盏生脉胶囊+西医常规治疗(0.08)>脑脉泰胶囊+西医常规治疗(0.06)>通心络胶囊+西医常规治疗(0.00)>西医常规治疗(0.00);在降低神经功能评分方面,概率排序为消栓肠溶胶囊+西医常规治疗(0.67)>通心络胶囊+西医常规治疗(0.21)>复方地龙胶囊/片+西医常规治疗(0.06)>脑心通胶囊+西医常规治疗(0.03)>灯盏生脉胶囊+西医常规治疗(0.02)>脑脉泰胶囊+西医常规治疗(0.01)>西医常规治疗(0.00);在提高日常生活能力评分方面,概率排序为消栓肠溶胶囊+西医常规治疗(0.60)>脑心通胶囊+西医常规治疗(0.29)>通心络胶囊+西医常规治疗(0.07)>复方地龙胶囊/片+西医常规治疗(0.04)>灯盏生脉胶囊+西医常规治疗(0.01)>西医常规治疗(0.00)。结论不同益气活血类中成药联合西医常规治疗在脑梗死恢复期的疗效方面均优于单用西医常规治疗,但因各中成药在不同结局指标中疗效排序差异较大,且纳入文献质量不高,故尚需开展大规模、高质量临床研究。Objective To compare the clinical efficacy of different Yiqi Huoxue Chinese patent medicines in the treatment of recovery period of cerebral infarction(CI)by network Meta-analysis.Methods Domestic and foreign databases including CNKI,Wanfang,VIP,PubMed,EMbase,Cochrane Library were systematically searched from inception to February 2021.Two authors independently extracted the literature data and evaluated the quality of literatures.Then Stata 16 and GeMTC 14.3 were used for network Meta-analysis.Results Finally,45 studies and 4355 cases were included,involving six kinds of Yiqi Huoxue Chinese patent medicines.The results of the Meta-analysis showed that in terms of improving total effective rate,the probability order was Naoxintong Capsule(脑心通胶囊)+western medicine treatment(0.59),Fufang Dilong Capsule/Tablet(复方地龙胶囊/片)+western medicine treatment(0.18),Xiaoshuan Changrong Capsule(消栓肠溶胶囊)+western medicine treatment(0.09),Dengzhan Shengmai Capsule(灯盏生脉胶囊)+western medicine treatment(0.08),Naomaitai Capsule(脑脉泰胶囊)+western medicine treatment(0.06),Tongxinluo Capsule(通心络胶囊)+western medicine treatment(0.00),western medicine treatment(0.00);in terms of decreased neurological function score,the probability order was Xiaoshuan Changrong Capsule+western medicine treatment(0.67),Tongxinluo Capsule+western medicine treatment(0.21),Fufang Dilong Capsule/tablet+western medicine treatment(0.06),Naoxintong Capsule+western medicine treatment(0.03),Dengzhan Shengmai Capsule+western medicine treatment(0.02),Naomaitai Capsule+western medicine treatment(0.01),western medicine treatment(0.00);in terms of improving the ability to live daily,the probability order was Xiaoshuan Changrong Capsule+western medicine treatment(0.60),Naoxintong Capsule+western medicine treatment(0.29),Tongxinluo Capsule+western medicine treatment(0.07),Fufang Dilong Capsule/tablet+western medicine treatment(0.04),Dengzhan Shengmai Capsule+western medicine treatment(0.01),western medicine treatment(

关 键 词：益气活血 中成药 脑梗死 缺血性卒中 网状Meta分析 脑心通胶囊 复方地龙胶囊/片 消栓肠溶胶囊 灯盏生脉胶囊 脑脉泰胶囊 通心络胶囊 

分 类 号：R285.64[医药卫生—中药学]